Mild Alzheimer’s patients benefit from 40Hz sensory stimulation in national clinical trial

At the Clinical Trials on Alzheimer's Disease conference in Boston Nov. 16, MIT spinoff company Cognito Therapeutics announced the results of its pivotal clinical trial of a noninvasive, device-based approach to Alzheimer's disease (AD) treatment first discovered in The Picower Institute in 2014.

The 395-member mild group benefited significantly, showing a slowed decline in three standard clinical measures of daily function and cognition relative to untreated controls. Among 169 “protocol-adherent” mild patients who used their devices at least 70% of the intended time, the benefits were more extensive.

The 268-member moderate group did not show clinical benefit, and mild patients did not show statistically significant benefit on some measures. All told, the overall study did not meet its primary endpoint. But based on the significant benefits seen in the mild population, Cognito executives said they would pursue FDA approval for use of their “Spectris” 40Hz light and sound stimulation goggles device (pictured above).

Sign up for Blog Updates